# Vyvanse

NDC: 59417-101
Generic name: lisdexamfetamine dimesylate
Labeler / Manufacturer: Takeda Pharmaceuticals America, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: New Drug Application (innovator)
Dosage form: CAPSULE
Routes: ORAL
Marketing started: 20140830

FDA application: NDA021977

## Active ingredients

- LISDEXAMFETAMINE DIMESYLATE: 10 mg/1

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"59417-101"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=59417-101
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=704e4378-ca83-445c-8b45-3cfa51c1ecad